Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Initial COVID-19 Vaccine Rollout Seems Bound To Disappoint

Executive Summary

National Academy of Medicines draft on equitable COVID-19 vaccine allocation needs more overt strategies to address equity, commenters say. Meanwhile, competing national and state efforts to address COVID-19 vaccination allocation could lead to confusion as the country struggles to fairly divide limited resources among many high-risk populations.

You may also be interested in...



COVID-19 Vaccines: US Distribution Plans Include ‘Data Lake’ For Centralized Tracking

Most vaccines will be distributed centrally by McKesson, but those with ultra-cold storage requirements will be shipped directly from the manufacturer to the vaccination site. Data exchange system will enable public and private databases to talk to each other and help ensure individuals receive timely revaccination with a second dose of the same vaccine regardless of location.

Warp Speed’s Woodcock Encourages Institutions To Continue COVID-19 Plasma Controlled Trial

Seeking to prevent negative fallout from emergency use authorization, Woodcock and NIH Director Collins ask investigators to prioritize a controlled trial of convalescent plasma currently underway in outpatients.

COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results

Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data. 

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS142854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel